deltatrials
Completed OBSERVATIONAL NCT04720599

Clinical Evaluation of ExoDx Prostate(IntelliScore) in Men Presenting for Initial Prostate Biopsy

Clinical Evaluation of ExoDx™ Prostate(IntelliScore) in Men Presenting for Initial Prostate Biopsy

Sponsor: Exosome Diagnostics, Inc.

Conditions Urologic Cancer
Interventions ExoDx Prostate(IntelliScore)
Updated 5 times since 2021 Last updated: Sep 29, 2021 Started: Jun 1, 2020 Primary completion: Jun 1, 2021 Completion: Jun 1, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates Urologic Cancer and is currently completed. Exosome Diagnostics, Inc. leads this study, which shows 5 recorded versions since 2020 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Feb 2021 – ~Oct 2021 · 8 months · monthly snapshotRecruiting~Oct 2021 – ~Jul 2024 · 33 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotCompleted~Sep 2025 – present · 10 months · monthly snapshotCompleted

Change History

5 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed

  2. Sep 2024 — Sep 2025 [monthly]

    Completed

  3. Jul 2024 — Sep 2024 [monthly]

    Completed

  4. Oct 2021 — Jul 2024 [monthly]

    Completed

    Status: Recruiting → Completed

  5. Feb 2021 — Oct 2021 [monthly]

    Recruiting

    First recorded

Jun 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Exosome Diagnostics, Inc.
Data source: Exosome Diagnostics, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations